A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
Brandon W. Higgs(Parker Institute for Cancer Immunotherapy), Yihong Yao(University of Science and Technology Beijing), Chris Morehouse, Xiang Guo, Laura K. Richman(University of Pennsylvania), Wendy I. White(University of North Carolina at Chapel Hill), David Fiorentino(Stanford University), Philip Z. Brohawn(Hofstra University), Bahija Jallal(Unknown), Steven A. Greenberg(Brigham and Women's Hospital), Wei Zhu(Ministry of Education of the People's Republic of China), Anthony A. Amato(Brigham and Women's Hospital), Marlon C. Rebelatto(AstraZeneca (Japan)), Jörn Drappa(Integrated BioTherapeutics (United States)), Chenxiong Le, Warren Greth
Cited by 168
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.
|Proceedings of the National Academy of Sciences|1991|752
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
|Cell|2020|546
Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1995|522